Leerink Partnrs Issues Pessimistic Outlook for PRCT Earnings

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – Analysts at Leerink Partnrs decreased their Q1 2025 earnings per share estimates for shares of PROCEPT BioRobotics in a research report issued on Tuesday, February 25th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings per share of ($0.47) for the quarter, down from their previous forecast of ($0.33). The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for PROCEPT BioRobotics’ Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.47) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.57) EPS and FY2028 earnings at $0.03 EPS.

Several other equities analysts have also recently issued reports on PRCT. Morgan Stanley lowered their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research report on Wednesday. Wells Fargo & Company reiterated an “overweight” rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Truist Financial reiterated a “buy” rating and set a $90.00 price target (down from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday. Finally, Jefferies Financial Group started coverage on PROCEPT BioRobotics in a research report on Thursday, November 14th. They set a “hold” rating and a $95.00 price target on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $94.29.

PROCEPT BioRobotics Stock Down 1.0 %

Shares of PRCT stock opened at $64.34 on Friday. PROCEPT BioRobotics has a 1 year low of $45.56 and a 1 year high of $103.81. The stock has a market cap of $3.36 billion, a PE ratio of -32.99 and a beta of 1.03. The business’s fifty day moving average is $74.93 and its 200-day moving average is $79.84. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million.

Institutional Trading of PROCEPT BioRobotics

Several hedge funds and other institutional investors have recently modified their holdings of PRCT. Westfield Capital Management Co. LP acquired a new stake in shares of PROCEPT BioRobotics in the third quarter worth $72,563,000. FMR LLC boosted its position in PROCEPT BioRobotics by 11.9% during the fourth quarter. FMR LLC now owns 8,159,208 shares of the company’s stock valued at $656,979,000 after purchasing an additional 866,328 shares during the last quarter. Perpetual Ltd acquired a new stake in PROCEPT BioRobotics during the fourth quarter valued at $66,972,000. Wellington Management Group LLP boosted its position in PROCEPT BioRobotics by 38.8% during the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company’s stock valued at $120,051,000 after purchasing an additional 416,819 shares during the last quarter. Finally, Franklin Resources Inc. boosted its position in PROCEPT BioRobotics by 64.5% during the third quarter. Franklin Resources Inc. now owns 885,992 shares of the company’s stock valued at $64,669,000 after purchasing an additional 347,330 shares during the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

Insider Transactions at PROCEPT BioRobotics

In other news, CEO Reza Zadno sold 26,423 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $97.22, for a total value of $2,568,844.06. Following the completion of the sale, the chief executive officer now owns 152,762 shares of the company’s stock, valued at $14,851,521.64. This trade represents a 14.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Alaleh Nouri sold 28,092 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total value of $2,728,575.96. Following the completion of the sale, the executive vice president now directly owns 52,472 shares of the company’s stock, valued at approximately $5,096,605.36. This trade represents a 34.87 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).